Candida Glabrata: a Review of Its Features and Resistance

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 2013 Nov 20

PMID 24249283

Citations 122

Authors

C F Rodrigues

S Silva

M Henriques

Affiliations

Soon will be listed here.

Abstract

Candida species belong to the normal microbiota of the oral cavity and gastrointestinal and vaginal tracts, and are responsible for several clinical manifestations, from mucocutaneous overgrowth to bloodstream infections. Once believed to be non-pathogenic, Candida glabrata was rapidly blamable for many human diseases. Year after year, these pathological circumstances are more recurrent and problematic to treat, especially when patients reveal any level of immunosuppression. These difficulties arise from the capacity of C. glabrata to form biofilms and also from its high resistance to traditional antifungal therapies. Thus, this review intends to present an excerpt of the biology, epidemiology, and pathology of C. glabrata, and detail an approach to its resistance mechanisms based on studies carried out up to the present.

Citing Articles

In Vitro Assessment of Fluconazole and Cyclosporine A Antifungal Activities: A Promising Drug Combination Against Different Species.

Carton J, de-la-Fuente I, Sevillano E, Jauregizar N, Quindos G, Eraso E J Fungi (Basel). 2025; 11(2).

PMID: 39997427 PMC: 11856077. DOI: 10.3390/jof11020133.

meningitis in a patient with newly diagnosed acquired immunodeficiency syndrome from Sikkim, India.

Subba S, Sharma T, Dopthapa Y, Bhutia U, Sharma R Curr Med Mycol. 2025; 10:e2024.345242.1542.

PMID: 39744337 PMC: 11688584. DOI: 10.22034/CMM.2024.345242.1542.

Evaluation of Fifteen 5,6-Dihydrotetrazolo[1,5-]quinazolines Against : Integrating In Vitro Studies, Molecular Docking, QSAR, and In Silico Toxicity Assessments.

Antypenko L, Antypenko O, Fominichenko A, Karnaukh I, Kovalenko S, Arisawa M J Fungi (Basel). 2024; 10(12.

PMID: 39728312 PMC: 11728297. DOI: 10.3390/jof10120816.

Antibiofilm Activity of PDMS/TiO against through Inhibited Hydrophobic Recovery.

Nguyen K, Sao L, Kyllo K, Hernandez D, Salomon S, Shah K ACS Omega. 2024; 9(41):42593-42601.

PMID: 39431067 PMC: 11483912. DOI: 10.1021/acsomega.4c07869.

Clinical and epidemiological aspects of yeast infections and rational use of antifungals.

Neto Junior J, Dias V, de Andrad Bastos V, de Andrade Bastos L, Bastos A, Bastos R Future Microbiol. 2024; 19(7):577-584.

PMID: 38884219 PMC: 11229581. DOI: 10.1080/17460913.2024.2342679.

References

Dujon B, Sherman D, Fischer G, Durrens P, Casaregola S, Lafontaine I . Genome evolution in yeasts. Nature. 2004; 430(6995):35-44. DOI: 10.1038/nature02579. View

Niimi M, Kamiyama A, Tokunaga M . Respiration of medically important Candida species and Saccharomyces cerevisiae in relation to glucose effect. J Med Vet Mycol. 1988; 26(3):195-8. View

Mah T, OToole G . Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 2001; 9(1):34-9. DOI: 10.1016/s0966-842x(00)01913-2. View

Marcos-Arias C, Eraso E, Madariaga L, Aguirre J, Quindos G . Phospholipase and proteinase activities of Candida isolates from denture wearers. Mycoses. 2009; 54(4):e10-6. DOI: 10.1111/j.1439-0507.2009.01812.x. View

Gutierrez-Escribano P, Zeidler U, Suarez M, Bachellier-Bassi S, Clemente-Blanco A, Bonhomme J . The NDR/LATS kinase Cbk1 controls the activity of the transcriptional regulator Bcr1 during biofilm formation in Candida albicans. PLoS Pathog. 2012; 8(5):e1002683. PMC: 3349750. DOI: 10.1371/journal.ppat.1002683. View

Iraqui I, Garcia-Sanchez S, Aubert S, Dromer F, Ghigo J, dEnfert C . The Yak1p kinase controls expression of adhesins and biofilm formation in Candida glabrata in a Sir4p-dependent pathway. Mol Microbiol. 2005; 55(4):1259-71. DOI: 10.1111/j.1365-2958.2004.04475.x. View

Alexander B, Johnson M, Pfeiffer C, Jimenez-Ortigosa C, Catania J, Booker R . Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013; 56(12):1724-32. PMC: 3658363. DOI: 10.1093/cid/cit136. View

Cox G, Harrison T, McDade H, Taborda C, Heinrich G, Casadevall A . Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun. 2002; 71(1):173-80. PMC: 143417. DOI: 10.1128/IAI.71.1.173-180.2003. View

Nakagawa Y, Kanbe T, Mizuguchi I . Disruption of the human pathogenic yeast Candida albicans catalase gene decreases survival in mouse-model infection and elevates susceptibility to higher temperature and to detergents. Microbiol Immunol. 2003; 47(6):395-403. DOI: 10.1111/j.1348-0421.2003.tb03376.x. View

10.

LaFleur M, Qi Q, Lewis K . Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrob Agents Chemother. 2009; 54(1):39-44. PMC: 2798516. DOI: 10.1128/AAC.00860-09. View

11.

Vazquez J, Sanchez V, Dmuchowski C, Dembry L, Sobel J, Zervos M . Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis. 1993; 168(1):195-201. DOI: 10.1093/infdis/168.1.195. View

12.

Bandara H, Lam O, Watt R, Jin L, Samaranayake L . Bacterial lipopolysaccharides variably modulate in vitro biofilm formation of Candida species. J Med Microbiol. 2010; 59(Pt 10):1225-1234. DOI: 10.1099/jmm.0.021832-0. View

13.

Ferrari S, Sanguinetti M, Torelli R, Posteraro B, Sanglard D . Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata. PLoS One. 2011; 6(3):e17589. PMC: 3052359. DOI: 10.1371/journal.pone.0017589. View

14.

Sardi J, Scorzoni L, Bernardi T, Fusco-Almeida A, Mendes Giannini M . Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2012; 62(Pt 1):10-24. DOI: 10.1099/jmm.0.045054-0. View

15.

Seider K, Brunke S, Schild L, Jablonowski N, Wilson D, Majer O . The facultative intracellular pathogen Candida glabrata subverts macrophage cytokine production and phagolysosome maturation. J Immunol. 2011; 187(6):3072-86. DOI: 10.4049/jimmunol.1003730. View

16.

Helmerhorst E, Venuleo C, Sanglard D, Oppenheim F . Roles of cellular respiration, CgCDR1, and CgCDR2 in Candida glabrata resistance to histatin 5. Antimicrob Agents Chemother. 2006; 50(3):1100-3. PMC: 1426449. DOI: 10.1128/AAC.50.3.1100-1103.2006. View

17.

Kuhn D, Ghannoum M . Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs. 2004; 5(2):186-97. View

18.

Vazquez J, Dembry L, Sanchez V, Vazquez M, Sobel J, Dmuchowski C . Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol. 1998; 36(2):421-6. PMC: 104553. DOI: 10.1128/JCM.36.2.421-426.1998. View

19.

Hagerty J, Ortiz J, Reich D, Manzarbeitia C . Fungal infections in solid organ transplant patients. Surg Infect (Larchmt). 2003; 4(3):263-71. DOI: 10.1089/109629603322419607. View

20.

Silva S, Henriques M, Hayes A, Oliveira R, Azeredo J, Williams D . Candida glabrata and Candida albicans co-infection of an in vitro oral epithelium. J Oral Pathol Med. 2010; 40(5):421-7. DOI: 10.1111/j.1600-0714.2010.00981.x. View